Generic manufacturers increasingly use IPR as a first-move option against delivery-system patents, particularly formulation patents on extended-release products where the prior art landscape includes academic publications on polymer matrix technology that may anticipate or render obvious the challenged claims
To view or add a comment, sign in More Relevant Posts Peptide Update Theres a post going around saying the FDA is moving 14 peptides like BPC-157, CJC-1295, Ipamorelin, GHK-Cu and others from Category 2 to Category 1, which would supposedly make them FDA-recognized and legally prescribable
doi: 10.3389/fmolb.2025.1724944 Received 14 October 2025 Revised 18 November 2025 Accepted 30 November 2025 Published 18 December 2025 Volume 12 - 2025 Edited by Maria Barile, University of Bari Aldo Moro, Italy Reviewed by Anna Maria Giudetti, University of Salento, Italy Maria Tolomeo, National Research Council (CNR), Italy Updates Copyright 2025 Schrder, Jalilvand, Kahl, Kaiser and Liebau
Anti-inflammatory effects: Rather than broadly suppressing inflammation, BPC-157 appears to modulate inflammatory responses toward healing rather than chronic inflammation
Consume prunes and prune juice
A Summary of Hims & Hers Pricing Semaglutide is all the hype right now
